Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson(Vanderbilt University Medical Center), Joseph I. Clark(Loyola University Medical Center), Carolin Bender(Heidelberg University), Alexander M. Menzies(The University of Sydney), Patrick A. Ott(Dana-Farber Cancer Institute), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Donald P. Lawrence(Massachusetts General Hospital), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Tejaswi Mudigonda(Vanderbilt University Medical Center), Elizabeth I. Buchbinder(Massachusetts General Hospital), Jessica C. Hassel(German Cancer Research Center), Georgina V. Long(The University of Sydney), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Matteo S. Carlino(The University of Sydney), Kristen Spencer(Rutgers Cancer Institute), Howard L. Kaufman(Rutgers, The State University of New Jersey), Fei Ye(University of Miami), Jenny Lee(Blacktown & Mount Druitt Hospital), Ryan J. Sullivan(Dana-Farber Cancer Institute), Janice M. Mehnert(NYU Langone Health), Alexander Guminski(The University of Sydney)
Cited by 656
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k